Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Gets Expanded Indication for Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

GSK Gets Expanded Indication for Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline received approval from the FDA for Hycamtin in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Following a six-month priority review by the FDA, the expanded indication is based on Phase III results that demonstrated a survival advantage by using Hycamtin in combination with cisplatin compared to cisplatin alone.

The randomized, multicenter trial found that Hycamtin, in combination with cisplatin, was effective in treating cervical cancers, which were not amenable to curative treatment with surgery and/or radiation therapy. The study showed a statistically significant improvement in overall survival for Hycamtin plus cisplatin arm. Median survival for Hycamtin plus cisplatin was 9.4 months when compared to 6.5 months for cisplatin alone. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters